Medical Device | December 22, 2025
Abbott wins FDA & CE nod for groundbreaking premature infant heart device
The system is intended for some of the tiniest patients—premature infants weighing as little as two pounds
The system is intended for some of the tiniest patients—premature infants weighing as little as two pounds
The patent will lock in broad protection for the company’s lead therapy CardiolRx and its novel subcutaneous candidate CRD-38
Uncontrolled diabetes in pregnancy dramatically increases the risk of pre-eclampsia, stillbirth, birth injuries, and long-term cardiometabolic diseases
The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
Nearly 1 in 3 HbA1c test results fall within the diabetic range, while 1 in 4 individuals show signs of prediabetes
The device delivers clear, high-quality images to support accurate diagnoses across a broad range of patient groups
Building on the Merck Foundation’s longstanding commitment to advancing access to high-quality health care, new national initiative supports grants to 11 organizations across the country
_256_384.jpg)
Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
The product will be manufactured at Lupin’s Chhatrapati Sambhajinagar facility in India
Subscribe To Our Newsletter & Stay Updated
